The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with chronic obstructive pulmonary disease (COPD). That’s according to top-line, one-year data from two Phase 3 clinical trials —…

For people with chronic obstructive pulmonary disease (COPD), characterized by cough and shortness of breath, Anoro Elipta (umeclidinium-vilanterol) may work better than other approved COPD medications at reducing the risk of disease flares. That’s according to a new federally funded study that used U.S. insurance data to compare…

A novel test based on the levels and composition of certain proteins in mucus, called mucins, may help assess lung health in people with chronic obstructive pulmonary disease (COPD), according to a new study. Findings show that higher Mucin Quantitative Score (MUCQ) values were significantly associated with worse lung…